UNSPSC 51461604: Chondroitin/glucosamine/methylsulfonylmethane

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HA000. This VA Drug Class (HA000) classifies this compound as belonging to the group HERBS/ALTERNATIVE THERAPIES.

UNSPSC 51461604 Chondroitin/glucosamine/methylsulfonylmethane, a Commodity code, encompasses over-the-counter nutritional supplements and joint-health products that state and local health systems, correctional facilities, and social-service agencies procure through cooperative purchasing vehicles and direct solicitations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently issued an RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. State and local issuing bodies under this code include state health departments, state procurement offices, counties, municipalities, and institutional buyers (correctional facilities, public health clinics, social-service agencies). Vendors must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with chargeback systems in place, and carry comprehensive insurance including workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.

The MMCAP RFP (S1070000015802) closed March 26, 2026, with questions due February 18, 2026. Awarded vendors will be provided to wholesalers by May 15, 2026, with contracts effective July 1, 2026. The contract term is two years for new responders with optional extensions at MMCAP's sole discretion; incumbent responders' amendments align with existing expiration dates through June 30, 2028. Evaluation weights pricing (75 percent), price competitiveness and format compliance (20 percent total), EDI capability and administrative-fee agreement (10 percent total). All products must comply with FDA requirements, possess expiration dates of at least one year from manufacture with a minimum six-month shelf life, and be available in the marketplace by May 15, 2026. Vendors pay a 3 percent administrative fee on all contract purchases and face performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Specific award values or budget ranges are not disclosed.